• Skip to main content
  • Skip to secondary menu
  • Skip to footer

ESN.net

event sharing network

  • Share Your Event
    • Make a Contribution
  • Events
  • Job Board
  • Markets
  • About
    • Event Marketing: A Catalyst for Business Success
    • Leveraging Social Media for Event Promotion: A Winning Strategy
    • Targeting the Right Audience: The Key to Successful Event Promotion
    • The Power of Media: Maximizing Event Promotion through the Media
    • Capturing the Moment: The Importance of Photo and Video Coverage in Event Promotion
    • Voices of the Event: The Power of Interviews as a Promotion Tool
    • The Power of Podcasts: Using Audio as a Tool for Event Promotion
    • Bridging the Gap: How Virtual Events Complement Physical Ones and Expand Reach and Audience
    • The Future is Now: How Innovation is Revolutionizing Event Management and Promotion
  • Contact

2021 ASCO Annual Meeting, June 4-8, 2021

May 11, 2021 By admin Leave a Comment

Genentech to Present Data From One of the Most Comprehensive Oncology Portfolios at the 2021 ASCO Annual Meeting Showcasing Advancements for People Living With Cancer
Data from the first positive Phase III study of a cancer immunotherapy in early, resected lung cancer

Studies in personalized healthcare exploring tumor agnostic treatments that demonstrate the impact of coupling biomarker testing with targeted therapies to develop individualized treatment plans

New data, and drug combination strategies for the treatment of lymphoma from the largest hematology portfolio in industry

SOUTH SAN FRANCISCO, Calif. – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from clinical trials of 19 approved and investigational medicines across 20 cancer types will be presented at the 2021 ASCO Annual Meeting, which will be held June 4-8, 2021. A total of 132 abstracts that include a Genentech medicine will be presented at this year’s meeting. These data advance oncology by showing the importance of making patient-centric treatment decisions and providing tailored medical care based on specific cancer types.

“We will be presenting data from across our diverse oncology portfolio that has the potential to help more people living with many types of cancers,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “We are particularly excited about our compelling immunotherapy data in lung cancer, which may provide new hope for patients with earlier stage disease.”

Focusing on earlier treatment and targeted lung cancer care

Positive results from the Phase III IMpower010 study will be presented that show Tecentriq® (atezolizumab) improved disease-free survival (DFS) in people with resected early-stage non-small cell lung cancer (NSCLC) compared to best supportive care – a first in cancer immunotherapy. This advance is significant, as half of all people with early-stage lung cancer today still experience a recurrence following surgery; therefore, treating lung cancer early, before it has spread, can provide the best opportunity for a cure. Additionally, updated data for GavretoTM (pralsetinib) in patients with advanced RET fusion-positive NSCLC, including in patients who are treatment naïve, will be reported. These data highlight the need for early RET fusion-positive testing to identify candidates who may benefit from treatment with Gavreto.

Exploring personalized cancer care for more patients

Genentech will present several studies that take tumor-agnostic approaches to clinical development, and in breast cancer, that may benefit people with rare and common tumors alike. These studies bring together next-generation sequencing, targeted therapies and patient-centric clinical trial design that show how personalized treatment plans are helping to evolve the way people are treated. The Phase II ALPHA-T study, made possible through a collaboration with Foundation Medicine and Science37, is pioneering a decentralized approach to clinical trial design which enables patients to participate from their own homes while remaining under the care of their oncologist. The Phase II TAPISTRY study, a platform umbrella trial, will pair patients with immunotherapy, targeted therapy or treatment combinations based on distinct tumor biology characteristics. The similarly designed Phase II MyTACTIC study is enrolling a diverse population of patients to direct them to appropriately targeted treatments based on the results of comprehensive genomic profiling.

With our research we are contributing to the body of evidence in hormone receptor (HR)-positive breast cancer, the most prevalent type of all breast cancers. For giredestrant, a third-generation oral selective estrogen receptor degrader (SERD), we will present data further supporting the tolerable safety profile and single agent clinical activity, as well as pharmacodynamics data from studies in HR-positive early and metastatic breast cancer.

Defining new solutions for patients with difficult-to-treat blood cancer

New and updated data in non-Hodgkin lymphoma (NHL) will be shared, including data from the T-cell engaging CD20xCD3 bispecific antibody development program. Glofitamab and mosunetuzumab are both T-cell engaging CD20xCD3 bispecific antibodies that are being studied as single agents or in combination with other Genentech therapies. Together, they may offer a new immunotherapy-based approach to tackle a range of blood cancers. In addition, data exploring novel combinations with mosunetuzumab and Polivy® (polatuzumab vedotin), an antibody-drug conjugate, will also be featured. These data demonstrate how Genentech continues to seek new solutions for people living with a range of malignant blood disorders, where treatment options are still limited and both relapse and treatment resistance are common.

Furthermore, Genentech’s data showcase a commitment to health equity through medicine delivery approaches that reduce treatment time and cost, trial designs that help remove barriers to clinical trial participation, pioneering cancer immunotherapy to improve outcomes for earlier disease stages, and a focus on inclusivity through developing tumor-specific therapies and therapy combinations based on the specific characteristics of each person’s disease.

Source: Genentech
Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.

Filed Under: events

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Footer

Recent Posts

  • Agile Software Development Workshop, March 22, 2023
  • GameDev Workshop, From March 10, 2023
  • VPNW 2023, VPN Workshop, March 15, 2023
  • Virtual Job Fair Connects Job Seekers Around the Globe with Employers, February 25, 2023
  • Cloudflare Developer Meetup of 2023, March 16, 2023, Lisbon, Portugal
  • The Electric Vehicles Battery Tech USA Conference is scheduled to take place on March 6-7, 2023 at the Hyatt Regency Orange County
  • The IFA Annual Convention brings together professionals from the franchising industry, February 26 – March 01, 2023, in Las Vegas, NV
  • Tech Summit 2023 explored game-changing technology trends
  • LEX Summit, a legal conference, February 12-15, 2023, at the Hyatt Regency Hotel in Salt Lake City, Utah
  • Essential Considerations for Event Registration and Attendance Management

Media Partners

  • Calendarial
  • Technology Conferences
  • Event Calendar
Art Calendar: Today marks the Feast Day of Saint Nicholas
Transforming Transportation 2023, March 14-15, 2023, World Bank HQ, Washington, DC
How to manage calendar of corporate events
ABF Freight to Host Dayton-Area Hiring Event, November 12, 2022, Dayton
World Cancer Day is an international observance held annually on February 4th
PIE Astronomical Telescopes + Instrumentation Symposium, 17-22 July 2022, Montréal
The RISC-V Summit will be held at Moscone West in San Francisco from December 6-8, 2021
KubeCon+CloudNativeCon, October 11-15, 2021, in person in Los Angeles or virtually
Future Compute, Tuesday, May 3, 2022 – Wednesday, May 4, 2022
Oracle CloudWorld Las Vegas, October 17-20, 2022
Gulfood 2022, the world’s largest food and beverage B2B event, February 13-17, 2022, Dubai World Trade Center
KOREA PACK & ICPI WEEK (Int’l Cosmetic and Pharmaceutical Industry Week) 2022, June 14-17 2022, Kintex
Prints 2023, Printing Conference, March 3, 2023
On February 14th and 15th, 2023, the 29th International Mediterranean Tourism Market (IMTM) will be held at the Expo Tel Aviv
Tomorrow Mobility will showcase new disruptive and sustainable urban vehicles, November 16-18, 2021, Fira de Barcelona

Media Partners

  • Technologies.org
  • 3v.org
  • Market Analysis
The Timeline for the Global Phase-Out of Gasoline and Diesel-Powered Cars
Revolutionizing the Fashion Industry: Algae-based Yarns and Dyes Take on Fast Fashion
The Need for 6G Technology: Challenges and Opportunities
Software Engineer with Legacy Systems Experience
Exploring the Latest Trends in Virtual Merchandising for Enhanced Online Shopping Experiences
Token Announces $13 Million Series B Funding Round and Appointment of New CEO to Disrupt the Authentication Market
Volvo Group has launched a new track for early-stage startups at its global innovation hub, CampX
Sublime Systems Secures $40 Million Series A to Electrify and Scale Decarbonized Cement Production
Nucleo Raises $4 Million Seed Round to Build Privacy Crypto Infrastructure for Organizations
LOCUS ROBOTICS ANNOUNCES $117 MILLION IN SERIES F FUNDING, BRINGING ITS VALUATION CLOSE TO $2 BILLION
Carbon-free trucks are becoming increasingly viable alternatives to traditional diesel-powered trucks
Computer chips have become the center of a fight between global superpowers
How to create urban developments with a competitive streak
The state of holographic display technology for AR gaming
Why are fertilizer prices out of reach for most farmers in developing countries?

Copyright © 2022 ESN.net

Media Partners: Technologies, Market Analysis & Market Research and Exclusive Domains

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT